Stock Financial Ratios, Dividends, Split History

WEN / The Wendy's Company financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,427.67
Enterprise Value ($M)7,010.63
Book Value ($M)463.00
Book Value / Share1.94
Price / Book7.72
NCAV ($M)-3,204.43
NCAV / Share-13.40
Price / NCAV-1.34
Share Statistics
Common Shares Outstanding 239,414,307
Weighted Average Number Of Diluted Shares Outstanding 252,289,000
Common Stock Shares Outstanding 240,512,000
Weighted Average Number Of Shares Outstanding Basic 244,179,000
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.05
Return on Equity (ROE)0.37
Balance Sheet (mrq) ($M)
Quick Ratio1.76
Current Ratio1.77
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Franchise Revenue410,503,000.00
Sales Revenue Goods Net622,802,000.00
Number Of Customers Accounting For More Than10 Of Revenues0.00
Royalty Revenue0.00
Operating Income214.76
Net Income194.03
Earnings Per Share Basic0.79
Earnings Per Share Diluted0.77
Cash Flow Statement (mra) ($M)
Cash From Operations251.64
Cash from Investing-67.31
Cash from Financing-67.31
Identifiers and Descriptors
Central Index Key (CIK)30697
Related CUSIPS
95058W900 095058W10 95058W950

Split History

Stock splits are used by The Wendy's Company to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Wendy's (WEN) Strategic Plans Bode Well: Should You Hold?

2018-06-08 zacks
Shares of The Wendy's Company (WEN - Free Report) are riding high on robust rental revenues, franchise-based business model, restaurant openings and menu innovations. Evidently, the stock has gained 10.5% in a year, outperforming the industry’s increase of 4%. However, higher labor and commodity costs along with capital spending might weigh on margins, going ahead. Let’s delve deeper. (22-0)

Wendy's (WEN) Down 3.5% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
It has been about a month since the last earnings report for The Wendy's Company (WEN - Free Report) . Shares have lost about 3.5% in that time frame. (25-0)

Dave & Buster's: It's All Fun And Games With Nearly 30% Upside

2018-05-22 seekingalpha
Casual-dining chains have not been winners during this economic expansion. Millennials, with their need for more social media-worthy experiences, have been blamed for the decline. (49-0)

Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66, Valero and Many More

2018-05-17 247wallst
Stocks have seen a recovery for much of the week, but major equity indexes were all marginally lower on Thursday morning. The trend of endless buying the dips has not worked well lately, and many investors are wondering whether the best has been seen for 2018. Now all investors have to consider how they want their investments positioned for the longer term. (898-5)

Wendy's: A Look At Q1

2018-05-13 seekingalpha
Wendy's reported earnings this week, delivering mixed results. Shares were sent sliding on light store comps. (1-0)

CUSIP: 95058W100